CDEK
← All organizations

G1 Therapeutics, Inc.

For profitContributed to NMEWebsite ↗

Also known as: G1 THERAP | G1 Therapeutics, Inc.

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Sep 1, 2014

First marketed drug

Feb 12, 2021

First NDA

Feb 12, 2021

Last known activity

Dec 31, 2023

Timeline

2000s

  1. Jun 1, 2008

    G1 Therapeutics, Inc.— Founded

2020s

  1. Feb 12, 2021

    trilaciclib— Marketing Organization

  2. Feb 12, 2021

    trilaciclib— NDA Organization

  3. Feb 12, 2021

    trilaciclib— NDA Secondary Org

Drugs by trial phase (20 distinct, 21 trials)

Phase 4 (2 own, 0 via acquisition)

Phase 3 (2 own, 0 via acquisition)

Phase 1 (2 own, 0 via acquisition)

Indications

Studied for

Marketed drugs (1)

Recent trials (33)

Details

Founded
Durham, North Carolina, US Jun 1, 2008
First NDA
Feb 12, 2021
Last known activity
Dec 31, 2023

Designations held

  • Priority review
  • Breakthrough therapy